The introduction of generic versions of Ozempic in Canada is set to reduce costs and increase access to popular weight-loss medications, potentially making treatment more routine across the country.
Canada’s market for semaglutide is beginning to change in a way that could materially ease the cost of weight-loss treatment for many patients. According to Canadian pharmacy and pricing guides published this year, generic versions of Ozempic are now appearing in the country, with lower monthly costs than the brand-name product and wider competition expected to push prices down further as supply settles. The shift matters because semaglutide has become one of the most sought-after drugs in both diabetes care and obesity treatment, yet its out-of-pocket cost has kept many people from starting or staying on therapy.
That barrier has been especially pronounced for patients paying privately. Reviews of Ozempic’s use for weight loss in Canada note that the drug can produce average body-weight reductions of around 10% to 15% over a little more than a year, while higher-dose semaglutide sold as Wegovy can produce even greater losses. But those results have come with significant expense, and many insurers still draw a line between diabetes treatment and medicines prescribed for weight management, leaving patients to absorb much of the bill themselves.
The arrival of generic semaglutide is therefore being watched closely by patients, prescribers and pharmacies alike. One Canadian cost guide says generic Ozempic, sometimes referred to as Apo-Semaglutide, is already being listed at some outlets for between $88 and $99 depending on province, while other providers are marketing it from about $114 to $124.99 a month. Phoenix has said its generic semaglutide is available from $124.99 monthly, and that price comparisons vary depending on insurance and provincial coverage. Taken together, those figures suggest that the savings are real, though not yet uniform.
Even so, a lower price does not automatically mean instant access everywhere. Pricing trackers and pharmacy guides say availability still depends on local stock, dispensing arrangements and how quickly wholesalers and pharmacies take up the new product. Analysts following the rollout expect the market to become more predictable as more batches clear inspection and more pharmacies begin buying in volume. Some industry forecasts say monthly costs could settle closer to the $100 to $150 range if several generics compete for business, although that depends on how quickly the market matures.
The clinical picture also remains unchanged. Generic semaglutide is expected to work through the same active ingredient as brand-name Ozempic, and the point of bioequivalence is to ensure that it behaves similarly in the body. That said, patients are still advised to discuss any switch with a clinician, particularly if they have allergies, sensitivities or concerns about side effects. As with the branded version, gastrointestinal symptoms remain the most commonly cited issue, and treatment still needs to be part of a broader approach that includes diet, activity and long-term follow-up.
For now, the most significant effect of Canada’s generic rollout may be psychological as much as financial: a treatment long associated with sticker shock is becoming more accessible. If provincial formularies, private insurers and pharmacy supply chains continue to adjust, semaglutide could move from a premium option for a relatively small group of patients to something far closer to routine care. For many Canadians, that could be the difference between postponing treatment and finally being able to start it.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
